Under the arrangement, prices for GLP-1 drugs—used both for diabetes and obesity—will be slashed for Medicare and Medicaid ...

Popular GLP-1 drugs like Ozempic will get cheaper in exchange for partial Medicare coverage, opening up new markets for Eli ...

Even after Trump’s new deal, obesity drugs are still too expensive.

The deal is with drugmakers Eli Lilly and Novo Nordisk to cut prices of their weight-loss drugs and expand Medicare coverage ...

President Trump's plan drops the price of Ozempic and Wegovy for Americans, with plans for Medicare to cover the popular ...

A new US government deal with drugmakers Eli Lilly and Novo Nordisk will slash prices for popular weight-loss drugs like ...

Trump, Eli Lilly and Novo Nordisk unveiled a deal to slash the prices of popular GLP-1 weight‑loss drugs for government health insurance programs, as well as for cash payers.

Medicare will cover weight-loss drugs under a deal between the Trump administration and drugmakers Eli Lilly and Novo Nordisk ...

Popular GLP-1 drugs like Ozempic get cheaper in exchange for partial Medicare coverage, which opens up new markets for both companies ...

Denmark-based Novo Nordisk, which makes Ozempic, Rybelsus and Wegovy; and Indianapolis-based Eli Lilly, which makes Zepbound, ...

Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with ...